(0.38%) 5 119.30 points
(0.29%) 38 351 points
(0.43%) 15 997 points
(-1.31%) $82.75
(3.38%) $1.988
(0.01%) $2 347.50
(0.01%) $27.54
(3.09%) $950.55
(-0.04%) $0.934
(0.00%) $11.03
(-0.28%) $0.798
(1.84%) $93.56
Live Chart Being Loaded With Signals
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies...
Stats | |
---|---|
Dagens volum | 1 664.00 |
Gjennomsnittsvolum | 12 870.00 |
Markedsverdi | 25.09B |
Last Dividend | $0.726 ( 2023-05-01 ) |
Next Dividend | $0 ( N/A ) |
P/E | 70.31 |
ATR14 | $0.164 (0.25%) |
UCB SA Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
UCB SA Økonomi
Annual | 2023 |
Omsetning: | $5.25B |
Bruttogevinst: | $3.55B (67.50 %) |
EPS: | $1.810 |
FY | 2023 |
Omsetning: | $5.25B |
Bruttogevinst: | $3.55B (67.50 %) |
EPS: | $1.810 |
FY | 2022 |
Omsetning: | $5.52B |
Bruttogevinst: | $3.84B (69.64 %) |
EPS: | $2.20 |
FY | 2021 |
Omsetning: | $5.78B |
Bruttogevinst: | $4.34B (75.11 %) |
EPS: | $5.60 |
Financial Reports:
No articles found.
UCB SA Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0.726 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.663 | 2013-05-02 |
Last Dividend | $0.726 | 2023-05-01 |
Next Dividend | $0 | N/A |
Payout Date | 2023-05-18 | |
Next Payout Date | N/A | |
# dividends | 11 | -- |
Total Paid Out | $7.46 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.23 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 4.90 | |
Div. Directional Score | 8.72 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
MYBF | Ex Dividend Knight | 2023-10-04 | Quarterly | 0 | 0.00% | |
CODYY | Ex Dividend Knight | 2023-06-08 | Sporadic | 0 | 0.00% | |
SYIEY | Ex Dividend Knight | 2023-05-11 | Annually | 0 | 0.00% | |
HNHPF | Ex Dividend Junior | 2023-07-03 | Annually | 0 | 0.00% | |
ATLKY | Ex Dividend Knight | 2023-10-19 | Semi-Annually | 0 | 0.00% | |
OTGLY | Ex Dividend Junior | 2023-06-12 | Annually | 0 | 0.00% | |
DTCWY | Ex Dividend Junior | 2023-06-15 | Annually | 0 | 0.00% | |
TTDKF | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
JMHLY | Ex Dividend Knight | 2023-08-16 | Semi-Annually | 0 | 0.00% | |
BNPQY | Ex Dividend Junior | 2023-05-18 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0656 | 1.500 | 8.69 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0331 | 1.200 | 8.90 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0571 | 1.500 | -0.477 | -0.715 | [0.1 - 1] |
payoutRatioTTM | 0.490 | -1.000 | 5.10 | -5.10 | [0 - 1] |
currentRatioTTM | 1.317 | 0.800 | 8.42 | 6.73 | [1 - 3] |
quickRatioTTM | 0.839 | 0.800 | 9.77 | 7.81 | [0.8 - 2.5] |
cashRatioTTM | 0.329 | 1.500 | 9.28 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.196 | -1.500 | 6.74 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 4.50 | 1.000 | 9.45 | 9.45 | [3 - 30] |
operatingCashFlowPerShareTTM | 5.26 | 2.00 | 8.25 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 2.96 | 2.00 | 8.52 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.338 | -1.500 | 8.65 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.648 | 1.000 | 2.54 | 2.54 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.120 | 1.000 | 9.59 | 9.59 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.328 | 1.000 | 9.29 | 9.29 | [0.2 - 2] |
assetTurnoverTTM | 0.505 | 0.800 | 9.97 | 7.97 | [0.5 - 2] |
Total Score | 12.54 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 22.86 | 1.000 | 7.79 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0571 | 2.50 | -0.306 | -0.715 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 2.96 | 2.00 | 9.01 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 2.34 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 5.26 | 2.00 | 8.25 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.490 | 1.500 | 5.10 | -5.10 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.127 | 1.000 | 9.32 | 0 | [0.1 - 0.5] |
Total Score | 4.90 |
UCB SA
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer's disease; and UCB0599 to treat Parkinson's disease. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. It operates in the United States, Japan, Germany, rest of Europe, Spain, France, Italy, the United Kingdom, Ireland, China, Belgium, and internationally. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.